#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2020 - 5

Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague

Czech version

Authors: Miloš Bohoněk 1;  David Řezáč 2;  Michal Holub 2
Authors‘ workplace: Oddělení hematologie a krevní transfuze, ÚVN Praha 1;  Klinika infekčních nemocí 1. LF UK a ÚVN Praha 2
Published in: Čas. Lék. čes. 2020; 159: 175-180
Category: Review Article

Overview

One of the available treatment alternatives for COVID-19 is the administration of convalescent plasma (CP), blood plasma obtained from people who have undergone the disease. Administration of anti-SARS-CoV-2 antibodies in plasma is a method of passive specific immunization with an expected therapeutic response. CP can also be used for production a specific immunoglobulin. Experience from previous epidemic infections, caused by the coronaviruses SARS-CoV-1 and MERS-CoV, shows that CP contains neutralizing antibodies against the virus, which are probably the main source of its therapeutic potential. However, other immune mechanisms cannot be ruled out, such as antibody-induced cellular cytotoxicity and/or phagocytosis.

The use of CP for the treatment of COVID-19 spread during the first half of year 2020 in many countries worldwide and relatively common is also in the Czech Republic, where, at the end of August 2020, about 100 patients were treated with CP. The production and use of CP is governed by the national multidisciplinary guidelines from April 2020 and the recommended therapeutic dose are 2 TU RP (400-450 mL), resp. 4-6 mL/kg. CP is indicated mainly in severe cases of COVID-19, which require oxygen support, ideally within 2-3 days after diagnosis, but our and foreign experience shows a beneficial effect of CP even in moderately severe cases that do not need oxygen treatment.

Keywords:

SARS-CoV-2 – COVID-19 – convalescent plasma

Sources

  1. Woo PCY, Lau SK, Wong BH et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diag Lab Immunol 2004; 11: 665–668.

  2. Cheng Y, Wong R, So YOY et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44–46.

  3. Yeh KM, Chiueh TS, Siu LK et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56: 919–922.

  4. Zhang JS, Chen JT, Liu YX et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 2005; 77: 147–150.

  5. Arabi MA, Hajeer HA, Luke T et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 2016; 22: 1554–1561.

  6. Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al. The effectiveness of convalescent plasma and hyperimun immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80–90.

  7. Garroud O, Heshmati F, Pozzetto B et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol 2016; 23: 39–44.

  8. Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci 2020; 59: 102790.

  9. Cao H, Shi Y. Convalescent plasma: possible therapy for novel coronavirus disease 2019. Transfusion 2020; 60: 1078–1083.

  10. Tiberghien P, de Lamballiere X, Morel P et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang 2020, doi: 10.1111/vox.12926.

  11. Rajendran K, Krishnasamy N, Rangarajan J et al. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol 2020, doi: 10.1002/jmv.25961.

  12. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H1N1 treatment? Ann Intern Med 2006; 145: 599–609.

  13. Kraft CS, Hewlett AL, Koepsell S et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola Virus Disease in the United States. Clin Infect Dis 2015; 61: 496–502.

  14. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357: 1450–1451.

  15. Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52: 447–456.

  16. Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nature Microbiol Rev 2004; 2: 695–703.

  17. Use of convalescent whole blood or plasma collected from patients recovered from Ebola Virus Disease for transfusion, as an empirical treatment during outbreaks. WHO Interim Guidance for National Health Authorities and Blood Transfusion Services, Version 1.0, WHO/HIS/SDS/2014.8. World Health Organization, 2014.

  18. Sahr F, Ansumana R, Massaquoi TA et al. Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 2017; 74: 302–309.

  19. Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1979; 23: 23–31.

  20. Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 80–90.

  21. Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490–9496.

  22. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020; 323: 1561–1562.

  23. Joyner MJ et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020; 2020.08.12.20169359.

  24. Qu J. Wu C, Li X et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020, doi: 10.1093/cid/ciaa489

  25. Casadevall A, Scharff MD. "Serum therapy" revisited: Animal models of infection and the development of passive antibody therapy. Antimicrob Agents Chemotherap 1994; 38: 1695–1702.

  26. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130: 1545–1548.

  27. COVID-19: Transfuze rekonvalescentní plazmy. Evropská komise, 2020. Dostupné na: https://ec.europa.eu/health/blood_tissues_organs/covid-19_cs

  28. Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–1578.

  29. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A Review. JAMA 2020; 323: 1824–1836.

  30. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the treatment of Covid-19 - Preliminary Report. N Engl J Med 2020, doi: 10.1056/NEJMoa2007764.

  31. Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324: 1048–1057.

  32. Li L, Zhang W, Hu Y et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324: 460–470.

  33. Liu Z. Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA 2020; 324: 518–519.

  34. Xia X, Li K, Wu L et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood 2020; 136: 755–759.

  35. Guo L, Wei D, Zhang X et al. Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA Score. Front Microbiol 2019; 10: 2752.

  36. Clinical management of COVID-19: interim guidance. World Health Organization, 2020.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Úvodem
A case of severe course of COVID-19 treated with experimental therapy
Role of blood biomarkers in spontaneous intracerebral hemorrhage – a prospectively studied cohort of patients
Psychosomatic and psychosocial aspects of health risks perception rising from living and occupational settings
Gambling products and their risk potential for gambling disorder
New trends in teaching anatomy and our experience with teaching anatomy in Czech during quarantine regarding COVID-19 pandemic
Health care at the St. George Monastery at the Prague Castle in the 17th and 18th century
Custodial, corporal, capital punishment? Death in St. Wenceslas and Pankrac prisons 1827–1926
Zapomenutý gastroenterolog?
Opustila nás prof. Eva Seemanová
Zemřel nestor české ortopedie prof. Oldřich Čech
Article was published in

Journal of Czech Physicians

Issue 5
2020 Issue 5
Download issue PDF
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#